Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of ruxolitinib cream in children with nonsegmental vitiligo
2024-513171-41-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in nonsegmental vitiligo comparing Ruxolitinib cream with Vehicle (placebo) cream (2 arms). Primary endpoint: F-VASI75 response at Week 24. Planned start Sep 2025; status: authorised.
02
Drugs
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on 2024-513171-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513171-41-00.